Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

OC practice guidelines: minimizing side effects

P D Darney1

  • 1Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, University of California, San Francisco, USA.

International Journal of Fertility and Women'S Medicine
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing maternal mortality due to elective abortion: Potential impact of misoprostol in low-resource settings.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2007
Same author

Contraception-associated menstrual problems: etiology and management.

Dialogues in contraception·2002
Same author

Practice guidelines for OC selection: update.

Dialogues in contraception·2002
Same author

Implant contraception.

Seminars in reproductive medicine·2001
Same author

Misoprostol: a boon to safe motherhood...or not?

Lancet (London, England)·2001
Same author

Time to pardon the IUD?

The New England journal of medicine·2001
Same journal

The paradox of obstetric "near misses": converting maternal mortality into morbidity.

International journal of fertility and women's medicine·2008
Same journal

Fibroid volume, location and symptoms in women undergoing uterine artery embolization: does size or position matter?

International journal of fertility and women's medicine·2008
Same journal

Umbilical cord rupture: a case report and review of literature.

International journal of fertility and women's medicine·2008
Same journal

A continuum of care model for postpartum hemorrhage.

International journal of fertility and women's medicine·2008
Same journal

Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.

International journal of fertility and women's medicine·2008
Same journal

Value of fetal echocardiography in diagnosis of congenital heart disease in a Serbian university hospital.

International journal of fertility and women's medicine·2008
See all related articles

Selecting the right oral contraceptive (OC) can minimize side effects like acne and breakthrough bleeding. Low-androgenic OCs improve androgen-related symptoms and metabolic profiles, enhancing tolerability and adherence.

Area of Science:

  • Endocrinology
  • Gynecology
  • Pharmacology

Background:

  • Side effects of oral contraceptives (OCs) are common causes for discontinuation.
  • Physical side effects such as weight gain, nausea, and mood swings impact adherence.
  • The androgenicity of progestins in OCs influences side effect profiles.

Purpose of the Study:

  • To evaluate how OC formulation, specifically progestin androgenicity, affects common side effects.
  • To determine the impact of low-androgenic OCs on physical and metabolic adverse effects.
  • To provide guidance on OC selection for minimizing discontinuation.

Main Methods:

  • Review of studies comparing OCs with varying progestin androgenicity.
  • Analysis of reported side effects including breakthrough bleeding, acne, and metabolic changes.

Related Experiment Videos

  • Assessment of OC effects on weight, mood, and cardiovascular risk markers.

    • Main Results:

    • Low-androgenic OCs can improve or eliminate acne and hirsutism.
    • Weight changes are minimal regardless of OC androgenicity; smoking increases breakthrough bleeding.
    • Low-estrogen OCs with less androgenic progestins offer acceptable bleeding patterns.
    • Newer formulations with low-androgenic progestins favorably impact lipid profiles without significant carbohydrate metabolism effects.

    Conclusions:

    • Appropriate OC selection, particularly formulations with low progestin androgenicity, can minimize common side effects.
    • Low-androgenic OCs offer improved management of androgen-related conditions and potentially better metabolic profiles.
    • Understanding OC formulation components is key to enhancing patient adherence and therapeutic outcomes.